Novo Nordisk A/S (NYSE:NVO) finished Wednesday with a subtraction of -$1.58 to close at $187.59, a downside of -0.84 percent. An average of 3,238,380 shares of common stock have been traded in the last five days. There was a gain of $29.25 in the past week, and it reached a new high 48 times over the past 12 months. The last 20 days have seen an average of 1,682,430 shares traded, while the 50-day average volume stands at 1,419,580.
NVO stock has increased by 23.21% in the last month. The company shares reached their 1-month lowest point of $151.12 on 07/11/23. With the stock rallying to its 52-week high on 08/08/23, shares of the company touched a low of $95.02 and a high of $192.18 in 52 weeks. It has reached a new high 28 times so far this year and achieved 38.61% or $52.25 in price. In spite of this, the price is down -2.39% from the 52-week high.
Valuation Metrics
Novo Nordisk A/S (NVO) has a trailing price-to-earnings (P/E) ratio of 47.49. The stock’s beta is 0.44. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.72, the price-to-book (PB) ratio at 35.94.
The company has a payout ratio of 33.02%. The company’s most recent quarterly dividend payment was $1.1887 a share, representing a up of 103.68% from $0.5836 last year. Its latest increase dividend $0.6052 reported on Thursday February 2 2023.
Financial Health
The quick ratio of Novo Nordisk A/S for the three months ended March 30 was 0.70, and the current ratio was 0.90, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.30 and a total debt to equity ratio of 0.32 for the quarter ending March 30. Novo Nordisk A/S’s EBITDA margin for the year ending March 30 is 45.79%, while its operating margin for the same period stands at 42.80%. Its gross profit as reported stood at $21.03 billion compared to revenue of $25.06 billion.
Earnings Surprise
The analyst consensus anticipated Novo Nordisk A/S’s latest quarter earnings to come in at $1.27 per share, but it turned out to be $1.29, a 1.60% surprise. For the quarter, EBITDA amounted to $3.85 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Novo Nordisk A/S (NVO) price momentum. RSI 9-day as of the close on 09 August was 79.87%, suggesting the stock is Overbought, with historical volatility in this time frame at 79.70%.
As of today, NVO’s price is $170.45 +18.47% or $29.25 from its 5-day moving average. NVO is currently trading +21.22% higher than its 20-day SMA and +35.06% higher than its 100-day SMA. However, the stock’s current price level is +15.11% above the SMA50 and +80.27% above the SMA200.
The stochastic %K and %D were 76.77% and 50.31%, respectively, and the average true range (ATR) was 6.05. With the 14-day stochastic at 87.34% and the average true range at 5.02, the RSI (14) stands at 74.91%. The stock has reached 13.68 on the 9-day MACD Oscillator while the 14-day reading was at 15.36.
Analyst Ratings
HSBC Securities launched coverage on Novo Nordisk A/S (NYSE: NVO) in its analyst report released on July 14, 2023. The firm assigned the stock a Buy rating.
